ライフサイエンスコーパス: stroke

1 during the acute stage of a left hemisphere stroke.

2 ary end point, definite stent thrombosis, or stroke.

3 th aphasia due to unilateral left hemisphere stroke.

4 The clinical end point was ischemic stroke.

5 ed systolic and diastolic BP on large artery stroke.

6 m is a hallmark of ischaemic injury in acute stroke.

7 ociated with increased risk for BCVI-related stroke.

8 apeutic value of targeting immunity in human stroke.

9 nclude vaso-occlusion, hemolytic anemia, and stroke.

10 and 41% of recurrent strokes were ischaemic stroke.

11 tions of motor network connectivity in acute stroke.

12 r spoken word comprehension many years after stroke.

13 ve site have formed before producing a power stroke.

14 erosis and lead to myocardial infarction and stroke.

15 mplantation may offer improved recovery from stroke.

16 tly predicts early mortality after ischaemic stroke.

17 complications after AF-associated ischaemic stroke.

18 enting to hospital with a diagnosis of acute stroke.

19 ithin 3 months and 30 655 with no history of stroke.

20 o not receive treatment that could prevent a stroke.

21 ater than 0.16% in patients with acute minor stroke.

22 clinical recovery of patients with ischaemic stroke.

23 iovascular causes, myocardial infarction, or stroke.

24 ral S44189 in patients with recent ischaemic stroke.

25 as venous thromboembolism (VTE) and ischemic stroke.

26 s of patients who experience a perioperative stroke.

27 redicted PCOS with risk of diabetes, CHD, or stroke.

28 ms and valve prosthesis complication; or (3) stroke.

29 confirmed in an experimental mouse model of stroke.

30 consecutive cohort of patients with wake-up stroke.

31 nary heart disease, atrial fibrillation, and stroke.

32 or the treatment of ischemic and hemorrhagic stroke.

33 coronary heart disease (CHD) cases and 6,174 strokes.

34 ction, 0.94 (95% CI, 0.75-1.18) for ischemic stroke, 0.92 (95% CI, 0.75-1.12) for major bleeding, 0.5

35 nary events (1.64 [1.35, 2.00]) and ischemic stroke (1.87 [1.73, 2.01]).

36 After a first ischaemic stroke, 91% of recurrent strokes were also ischaemic str

37 ) increase in risk for small vessel ischemic stroke, a 197% increase (95% CI = 59-457%) in risk of in

38 = 44-113%) in risk for large artery ischemic stroke, a 57% (95% CI = 29-91%) increase in risk for sma

39 atients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg,

40 s include the harmonisation of resources for stroke across the whole patient journey (including the r

41 risk of CV death, myocardial infarction, or stroke (adjusted hazard ratio [HR], 1.23 [95% CI, 0.97-1

42 ter of differentiation)-84 in acute ischemic stroke after recanalization and to dissect the underlyin

43 91% of recurrent strokes were also ischaemic stroke; after an intracerebral haemorrhage, 56% of recur

44 Stroke alters the gut microbiota composition, and in tur

45 Racial/ethnic disparities in all-cause stroke among hemodialysis patients with atrial fibrillat

46 troke, and 1.35 [1.13, 1.61] for hemorrhagic stroke among men, while among women higher associated ri

47 , investigating racial/ethnic disparities in stroke among such patients is important to those who cou

48 1.27 ([95% CI, 1.12-1.45] P=2.87x10(-4)) for stroke and 3.05 ([95% CI, 1.92-4.85] P=2.30x10(-6)) for

49 gh with 30 days mortality of 31% in ischemic stroke and 42% in intracerebral hemorrhage.

50 In patients with ischaemic stroke and AF, predictors of d-sICH are different than t

51 aimed at reducing the risk of perioperative stroke and at improving the outcomes of patients who exp

52 consecutive patients admitted with ischemic stroke and atrial fibrillation.

53 Stroke and bleeding risk models have been created and va

54 erall, we observed remarkably lower rates of stroke and bleedings as predicted with CHA(2)DS(2)-VASc

55 ants with baseline cardiopulmonary diseases, stroke and cancer, 178,485 men and 267,202 women remaine

56 s of prediabetes in coronary artery disease, stroke and chronic kidney disease, complemented by a sys

57 poral evolution of vascular remodeling after stroke and demonstrate that a window of heightened vascu

58 ated by hyperreflexia in people with chronic stroke and facilitating greater intramuscular blood perf

59 to assess the role of inflammation in human stroke and for the development of adjunct treatments bey

60 r, namely malignant brain tumours, ischaemic stroke and haemorrhagic traumatic contusion.

61 eterminant of upper extremity recovery after stroke and has been described by the 70% proportional re

62 rior MI and IHD (all P<0.001) as well as AF, stroke and HF (all P=0.01) were more often seen in men,

63 ep slow waves in an animal model of ischemic stroke and identify sleep as a window for poststroke int

64 lay an important role in pathologies such as stroke and mental illness.

65 ombolytic treatment times for acute ischemic stroke and modestly lower 1-year all-cause and cardiovas

66 many forms of neurological injury, including stroke and nerve damage.

67 r Study (2011-2020) with suspected TIA/minor stroke and non-invasive angiography were included.

68 Bridging the gap between experimental stroke and patients by ischemic blood probing during the

69 consumption was consistently associated with stroke and peripheral artery disease across the differen

70 The primary efficacy outcome was stroke and the primary safety outcome was major bleeding

71 resonance images were obtained 12-weeks post-stroke and tissue was collected for immunohistochemistry

72 onary events, 1.65 [1.50, 1.80] for ischemic stroke, and 1.35 [1.13, 1.61] for hemorrhagic stroke amo

73 l-cause stroke, ischemic stroke, hemorrhagic stroke, and bleeding hospitalizations in ESRD patients t

74 All cause death, stroke, and cardiovascular event rates were similar betw

75 events (composite of myocardial infarction, stroke, and CVD mortality; hazard ratio [HR], 0.92 [95%

76 in vascular smooth muscle cell degeneration, stroke, and dementia.

77 n (AF) is associated with a risk of ischemic stroke, and functional myocardial imaging has offered no

78 were described and outcomes including death, stroke, and major bleeding at 30 days and 1 year were co

79 Post-ACS death, myocardial infarction, stroke, and overall major adverse cardiovascular or cere

80 rtic valve replacement (SAVR) for mortality, stroke, and rehospitalization.

81 Stroked animals developed impairment in long-term memory

82 e clinical profiles of individuals with post-stroke aphasia demonstrate considerable variation in the

83 ery, to identify fundamental domains of post-stroke aphasia.

84 diverse, graded variations observed in post-stroke aphasia.

85 principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a

86 number of deaths from any cause or disabling stroke at 1 year in the low-risk cohorts was 62, which i

87 TE neo bioprosthesis, was all-cause death or stroke at 1 year.

88 without previous ischaemic heart disease and stroke at recruitment were included, of whom 45 732 (42

89 hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile inter

90 prescribed as a treatment for spasticity in stroke, brain injury and multiple sclerosis patients, wh

91 reported, and associated with higher risk of stroke, but not quantitatively estimated.

92 perceived to convey a high risk of recurrent stroke, but two previous trials (SAMMPRIS and VISSIT) di

93 timing of onset and detection, perioperative stroke can be classified as intraoperative or postoperat

94 ge is to identify what elements of organised stroke care can be implemented to make the largest gain.

95 Because time is brain in stroke care, the speed with which a patient with large v

96 euroradiologist-labeled clinical DW positive stroke cases (CDB); (b) 2000 synthetic cases (S2DB); (c)

97 Stroke causes remodeling of vasculature surrounding the

98 ferent levels (comprehensive and primary) of stroke centre and telemedicine networks have been develo

99 ighly specialised treatment in comprehensive stroke centres) and the development of technology to imp

100 ary outcome was time to death or symptomatic stroke confirmed by imaging, assessed by a neurologist a

101 ading risk factor for dementia, how ischemic stroke contributes to this neurodegenerative condition i

102 ar neurology expertise for hospitals lacking stroke coverage, and its use has risen rapidly in the pa

103 carotid artery plaques (CAPs) in cryptogenic stroke (CS).

104 ovascular [CV] death, myocardial infarction, stroke), CV death/HHF, and progression of kidney disease

105 o Last, deletion of Bbeta2 rescued excessive stroke damage associated with dephosphorylation of Drp1

106 institutional review board-approved study, a stroke database of 962 cases (mean patient age +/- stand

107 Stroke decreases claudin-5 abundance, and we found that

108 pairment in long-term memory at 4-weeks post-stroke despite recovery from motor deficits, with hypert

109 determined the long-term risks of recurrent stroke, disability, quality of life, dementia and hospit

110 s, we enrolled patients with acute ischaemic stroke due to large vessel occlusion within a 12 h treat

111 Acute stroke during pregnancy or within 6 weeks of childbirth

112 073 [92%] confirmed by brain imaging) had a stroke during the study period.

113 Exposure to exertional heat stroke (EHS) has been linked to increased long-term decr

114 Exposure to exertional heat stroke (EHS) has been linked to increased susceptibility

115 Associations of CAC with incident CHD and stroke events were evaluated using multivariable-adjuste

116 e-based CAC interactions for ASCVD, CHD, and stroke events were observed.

117 ion and reclassification for CHD but not for stroke events.

118 plinary approach including neurologists with stroke expertise, whereas treatment of retinal vein occl

119 onal Institute of Neurological Disorders and Stroke for the randomisation phase and Vital Projects Fu

120 nd related the thalamus volume to time since stroke, gender, intracortical volume, age, and lesion vo

121 Patients with prior stroke had a higher stroke severity (median National Ins

122 ategies that have worked in rodent models of stroke have failed to provide protection in clinical tri

123 ciated with greater risk of subsequent MI or stroke (hazard ratio: 1.34; 95% confidence interval: 1.2

124 scular events (death, myocardial infarction, stroke, heart failure) and COVID-19 cardiorespiratory or

125 composite of incident myocardial infarction, stroke, heart failure, or CVD death) separately in white

126 including death, all-cause stroke, ischemic stroke, hemorrhagic stroke, and bleeding hospitalization

127 c neurological disorders, including ischemic stroke, hemorrhagic stroke, traumatic brain injury, Alzh

128 The advance of therapies to reduce the stroke impact of asymptomatic carotid artery stenosis ha

129 s over time in the prevalence of these acute stroke impairments.

130 ental enrichment during the chronic phase of stroke improves functional outcome in mice with no syner

131 of focal cerebral arteriopathy and ischemic stroke in a pediatric patient with coronavirus disease 2

132 t-term and long-term prognosis after a first stroke in low-income and middle-income countries, includ

133 atrial appendage occlusion (LAAO) to prevent stroke in patients with atrial fibrillation has been eva

134 ugh a PubMed search, we found that ischaemic stroke in people with migraine is strongly associated wi

135 itudinally and significantly decreases after stroke in the acute and subacute stages.

136 onal echocardiographic measures for ischemic stroke in the AF population but not incremental to globa

137 consistently associated with MI and ischemic stroke in the overall population.

138 atients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is planned.

139 ; HR, 1.37 [95% CI, 0.88-2.13]) and ischemic stroke (incidence rate, 5.6 versus 3.2 per 1000 person-y

140 Stroke induced significant bilateral B cell diapedesis i

141 We show that the stroke-induced asymmetry in a sensorimotor (cylinder) te

142 ing of cerebral reorganization by estimating stroke-induced changes in network connectivity aggregate

143 to increased susceptibility to a second heat stroke, infection and cardiovascular disease.

144 Stroke is a complex, time-sensitive, medical emergency t

145 The burden of stroke is higher in low-income and middle-income countri

146 Perioperative stroke is one of the most severe and feared complication

147 Stroke is the second leading cause of death worldwide an

148 rly discrimination of patients with ischemic stroke (IS) from stroke mimics (SMs) poses a diagnostic

149 cluding myocardial infarction (MI), ischemic stroke (IS), and peripheral artery disease (PAD).

150 fatality rates, and mean length of stay for stroke, ischaemic heart disease, and any cause in all re

151 compare outcomes including death, all-cause stroke, ischemic stroke, hemorrhagic stroke, and bleedin

152 f the limb corresponding to the sensorimotor stroke lesion site compared with spontaneous recovery an

153 Brain volumes with synthetic stroke lesions on DW images were produced by warping the

154 55 male patients; 449 scans with DW positive stroke lesions) and a normal database of 2027 patients (

155 attern of temporal dispersion independent of stroke location.

156 The carotid web is a proposed stroke mechanism that may underlie cryptogenic stroke, p

157 applied this framework to an acute ischemic stroke microsimulation model to calculate the difference

158 n of patients with ischemic stroke (IS) from stroke mimics (SMs) poses a diagnostic challenge.

159 e limitations of rodent or non-human primate stroke models, hundreds of putative neuroprotectants hav

160 ients were followed for 1 year for all-cause stroke, mortality, prescription medications, and cardiov

161 endpoint of cardiovascular death, all-cause stroke, myocardial infarction, or rehospitalization for

162 overy, and one patient died; (iii) ischaemic strokes (n = 8) associated with a pro-thrombotic state (

163 ing for patient characteristics and Sentinel Stroke National Audit Programme hospital score, a 1-unit

164 ess of CT angiography in patients with minor stroke (National Institutes of Health Stroke Scale [NIHS

165 onal Institute of Neurological Disorders and Stroke, National Institutes of Health.

166 -to-moderate acute noncardioembolic ischemic stroke (NIHSS score <=5) or TIA who were not undergoing

167 s associated with lower risk of small vessel stroke [odds ratio (OR) per standard deviation = 0.85, 9

168 e demonstrate that AAA4 controls the priming stroke of the motion-generating linker, which connects t

169 r thrombolysis, the risk of the composite of stroke or death within 30 days was lower with ticagrelor

170 rventional therapy in preventing symptomatic stroke or death.

171 ction (HR, 0.50 [95% CI, 0.26-0.97]) but not stroke or other cardiovascular end points.

172 to the spinal cord after damage (e.g., after stroke or spinal cord injury), possibly assisting recove

173 ted with an increased incidence of recurrent stroke or TIA: 2.32 versus 0.75 events per 100 patient-y

174 rrence of a cerebral ischaemic event (either stroke or transient ischaemic attack) or a further ICH f

175 roke recurrence after a cryptogenic ischemic stroke or transient ischemic attack (TIA).

176 th placebo in 4,731 participants with recent stroke or transient ischemic attack and no known coronar

177 f age and older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 6

178 MRI in individuals evaluated after ischemic stroke or transient ischemic attack.

179 e associated with lower risk of small vessel stroke (OR: 0.82, 95% CI = 0.75-0.89) and lower WMH volu

180 infarction or other acute coronary syndrome, stroke, or coronary revascularisation) per 1 mmol/L redu

181 all-cause mortality, myocardial infarction, stroke, or emergency cardiovascular hospitalization); an

182 te outcome of all-cause death, heart attack, stroke, or hospitalization for heart failure.

183 For tPA payments in acute ischemic stroke, our model-based results suggest financial incent

184 obiota dysbiosis has a substantial impact on stroke outcome by modulating the immune response.

185 lied for risk adjustment in population-based stroke outcomes research and in assessments of health sy

186 ge to the corticospinal tract, such as after stroke, partially contributing to functional recovery.

187 known to be well at Get With The Guidelines-Stroke participating hospitals between January 1, 2006,

188 ent presenting with recurrent unihemispheric strokes particularly when conventional vascular risk fac

189 roke mechanism that may underlie cryptogenic stroke, particularly in younger patients without vascula

190 validated in an independent cohort of acute stroke patients (n = 101) using model-based predictions

191 STATEMENT Amputation, peripheral injury, and stroke patients experience widespread alterations in neu

192 In this study, we found that stroke patients in the SLSR had a complexity of acute im

193 a prespecified post hoc analysis of ischemic stroke patients screened for DWI-fluid-attenuated invers

194 ts in a prospective cohort of 132 first-time stroke patients studied at 2 weeks post-injury (mean age

195 Short-term mortality in ICU-admitted stroke patients was high with 30 days mortality of 31% i

196 ate of acute kidney injury in acute ischemic stroke patients was low and was not higher in patients w

197 minogen activator; IV tPA) in acute ischemic stroke patients with prior ischemic stroke within 3 mont

198 ix up-regulated tRFs in a separate cohort of stroke patients, and independent datasets of small and l

199 out for the neurophysiological assessment of stroke patients, as well as an interesting target for re

200 mbulatory category (FAC) were graded for the stroke patients.

201 chanical thrombectomy (MT) in acute ischemic stroke patients.

202 year) accrued under current Medicare policy (stroke payment not adjusted for performance) compared wi

203 cortically-induced blindness, the early post-stroke period appears characterized by gradual-rather th

204 eart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease, cancer, liver-, rheum

205 ryptogenic stroke), the refinement of AF and stroke prediction schemes through comprehensive digital

206 In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol

207 dage occlusion in both primary and secondary stroke prevention for patients with atrial fibrillation,

208 Because stroke prevention is a major goal in the management of E

209 presents a framework of a potential upstream stroke prevention program with evidence-based implementa

210 been shown to confer equivalent benefits for stroke prevention with less bleeding risk and less tedio

211 nt nonadherence may be necessary to optimize stroke prevention.

212 Rate control, rhythm control, and stroke prophylaxis are the cornerstones of AF therapy.

213 zation of treatment strategies, ranging from stroke prophylaxis to monitoring of antiarrhythmic drug

214 Target: stroke quality initiative was associated with faster thr

215 curate triage, use of preclinical scales for stroke recognition, and deployment of novel technical so

216 ng beyond solely behaviour scores to explain stroke recovery and establish robust and discriminating

217 is the first study suggesting that the poor stroke recovery in aged mice can be reversed via poststr

218 ne oxidase 1), PON1, and APOE correlate with stroke recovery scores (R(2)=0.38-0.73, adjusted P<0.05)

219 may be a legitimate therapeutic approach for stroke recovery.

220 on the interplay between obesity and T2D in stroke recovery.

221 ardiac monitoring (ICM) in the prevention of stroke recurrence after a cryptogenic ischemic stroke or

222 After experimental stroke, reduced EphA4 levels improve functional outcome

223 Stroke reduction with direct oral anticoagulants (DOACs)

224 Behavioural deficits in stroke reflect both structural damage at the site of inj

225 In addition to adverse trends in stroke-related morbidity and mortality across the broade

226 ogy and prognosis, but its use in AF-related stroke remains limited.

227 Stroke remains one of the leading causes of permanent di

228 However, stroke remains the second leading cause of death worldwi

229 We confirmed that stroke results in impairments to specific motor domains

230 Individuals with stroke risk factors but without AF were recruited from t

231 fter adjustment for demographic factors, pre-stroke risk factors, and stroke subtype, the prevalence

232 ies for predicting, preventing, and managing stroke risk factors.

233 Dual antiplatelet therapy (DAPT) reduced stroke risk in high-risk transient ischemic attack (TIA)

234 DAPT was associated with reduced stroke risk in TIA patients with positive DWI (hazard ra

235 The 90-day stroke risk was higher in patients used monotherapy than

236 omic index, Charlson comorbidity, Framingham stroke risk, Sequential Organ Failure Assessment, durati

237 on, there are sociodemographic inequities in stroke risk.

238 gen levels on cardioembolic and large artery stroke risk.

239 care, PSM significantly reduced the risk of stroke (risk ratio [RR] 0.24, 95% CI 0.08-0.68).

240 minor stroke (National Institutes of Health Stroke Scale [NIHSS] score <=6) is not well established.

241 verity (median National Institutes of Health Stroke Scale, 11 [6-19] versus 11 [6-18]; absolute stand

242 George's Cognition and Neuroimaging in Stroke (SCANS; n=121) and Radboud University Nijmegen Di

243 he diagnosis and prognosis of acute ischemic stroke, septic shock, lung injuries, insulin resistance

244 The COMPASS study (Comprehensive Post-Acute Stroke Services) was a pragmatic cluster-randomized tria

245 reperfusion injury (IRI), in heart attack or stroke settings, but also as an unavoidable consequence

246 Patients with prior stroke had a higher stroke severity (median National Institutes of Health St

247 Baseline stroke severity adjusted regression model showed that ch

248 rsus those without (controls) with regard to stroke severity, rates of IVT/mechanical thrombectomy, s

249 Twenty-four hours after stroke, significantly more circulating platelet-neutroph

250 rt failure (HF), myocardial infarction (MI), stroke (ST), cardiovascular disease (CVD) and chronic ki

251 Recent stroke studies have shown that the ipsi-lesional thalamu

252 ons for Geographic and Racial Differences in Stroke) study participants with incident MI between 2003

253 that the balance of both healthy and chronic stroke subjects can be augmented through moments applied

254 ntralesional thalamus volume from 69 chronic stroke subjects' anatomical MRI data (age 35-92) and rel

255 raphic factors, pre-stroke risk factors, and stroke subtype, the prevalence of 3 out of the 8 acute i

256 h as depression and quality of life (QOL) in stroke survivor-care partner dyads.

257 s for improving social participation in post-stroke survivors, however it is unclear what the most ef

258 treatment within 8 hours after the onset of stroke symptoms in conjunction with standard care result

259 ban compared with warfarin for prevention of stroke/systemic embolism in patients with atrial fibrill

260 gy was associated with a higher incidence of stroke than the conservative strategy (hazard ratio, 3.7

261 populations (such as those with cryptogenic stroke), the refinement of AF and stroke prediction sche

262 infarction, coronary revascularization, and stroke through December 31, 2016.

263 ary outcomes were recurrent ischaemic event (stroke/TIA/systemic arterial embolism) and delayed sympt

264 controller enabled individuals with chronic stroke to remain standing for a factor of 2.5 longer on

265 warping the relative signal increase of real strokes to normal brain volumes.

266 ue lesions (e.g., cerebrovascular lesions in stroke) to identify functionally connected brain network

267 e effectiveness of a comprehensive postacute stroke transitional care (TC) management program.

268 ny neurological disorders including ischemic stroke, trauma, and chronic neurodegenerative diseases.

269 ders, including ischemic stroke, hemorrhagic stroke, traumatic brain injury, Alzheimer's disease, and

270 secutive patients with posterior circulation strokes treated with stent-retrievers at our center betw

271 classification (Trial of Org 10172 in Acute Stroke Treatment [TOAST]).

272 patient data from the Virtual International Stroke Trials Archive-ICH trials dataset, Clot Lysis: Ev

273 phone applications, telemedicine, and mobile stroke units.

274 osis of acute myocardial infarction (AMI) or stroke using International Classification of Diseases, 1

275 ain), other preclinical disease models (e.g. stroke), vascular-targeted therapeutics, and hemodynamic

276 ising these predictors may help inform early stroke versus d-sICH prevention strategies.

277 h corresponding increases in mean aqueductal stroke volume (14.6 muL; P = .045) and mean CSF peak-to-

278 /A ratio and 4D flow derived tricuspid valve stroke volume demonstrated independent association to he

279 Flow status was defined according to stroke volume index <35 mL/m(2) (low flow, LF) or >=35 m

280 max correlated with fluid-induced changes in stroke volume index in preload-dependent cases (r = 0.61

281 Stroke volume index was obtained by transpulmonary therm

282 cardiac motion, and better adherence to the stroke volume of the heart.

283 anges in hemodynamic parameters (heart rate, stroke volume, blood pressure, and peripheral blood flow

284 stemic vascular resistance, which constrains stroke volume, cardiac output and O(2) delivery, thereby

285 hin-hospital clustering, showed that target: stroke was associated with lower all-cause readmission (

286 r the other outcomes, although the number of strokes was small.

287 onditional Cxcr4 ablation in photothrombotic stroke, we find that Cxcr4 promotes initial monocyte inf

288 Causal effects of PCOS on risks of CHD and stroke were evaluated in European cohorts.

289 r a first ischaemic stroke, 91% of recurrent strokes were also ischaemic stroke; after an intracerebr

290 intracerebral haemorrhage, 56% of recurrent strokes were intracerebral haemorrhage, and 41% of recur

291 racerebral haemorrhage, and 41% of recurrent strokes were ischaemic stroke.

292 992 ischemic heart disease (IHD), and 42,951 strokes were recorded.

293 maximum rate of lever arm priming (recovery stroke) while slowing ATP hydrolysis, demonstrating that

294 argets for secondary prevention of ischaemic stroke, while factor VIII and gamma' fibrinogen require

295 mechanics and kinetics of the myosin working stroke with a smaller set of data.

296 or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 hours from the ti

297 is a 62-year-old woman who had an ischaemic stroke with massive haemorrhagic conversion requiring a

298 In acute ischemic stroke with unknown time of onset, magnetic resonance (M

299 treated with IV tPA who had a prior ischemic stroke within 3 months and 30 655 with no history of str

300 ischemic stroke patients with prior ischemic stroke within 3 months.

301 g the combined 1-year risk of death, MI, and stroke without increasing the risk of bleeding.